Role of ARNi in Ventricular Remodeling in Hypertensive LVH
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
In Singapore, hypertension is very common in the adult population. Hypertensive heart disease
is a leading cause of heart failure and cardiovascular death. Current management relies
primarily on achieving blood pressure targets. However, the optimal blood pressure goals are
controversial and there are inherent difficulties in measuring blood pressure using external
devices applied to peripheral arteries. As a result of (usually longstanding) hypertension,
the heart thickens (i.e. hypertrophies) to maintain function. Ultimately, HF may occur due to
long standing energy deficits, muscle injury/death and diffuse interstitial fibrosis (heart
muscle scarring). In an ongoing study (REMODEL, ClinicalTrial.gov Identifier NCT02670031), we
have been able to undertake preliminary analyses with respect to factors associated with the
development of fibrosis. In this randomize controlled trial, we will be examining a novel
therapy that has the potential to induce regression cardiac hypertrophy and fibrosis.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart Centre Singapore
Collaborator:
National Medical Research Council (NMRC), Singapore
Treatments:
Hydrochlorothiazide LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan